Switching antiviral medicine for hepatitis B after liver transplant
Part of Digestive system, Infections, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests whether switching to a newer antiviral medicine called tenofovir alafenamide (TAF, a pill for hepatitis B) is safe and works well for people who have had a liver transplant. The goal is to keep the liver healthy and reduce side effects compared to current treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 19 years of age or older.
- Your liver transplant must have been stable for at least one year, with normal liver enzyme levels (ALT and AST below 3 times the upper limit).
- You must currently be taking an antiviral medicine for hepatitis B other than tenofovir alafenamide (TAF).
- Your tacrolimus (anti-rejection medicine) level must be between 3 and 10 ng/mL.
- You must not have other organ transplants, re-transplants, or active infections like hepatitis C or HIV.
- You must be willing to use effective contraception during the trial if applicable.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies how well nucleoside (nucleoside-acid) type antiviral medicines control hepatitis B in people whose liver enzyme test (ALT) is currently normal. It may help those with active hepatitis B but no major liver inflammation on recent bloodwork.
This trial tests whether switching from the regular entecavir pill to a new orally dissolving version works just as well and is safe for patients who have had a liver transplant due to hepatitis B. If you've been stable on entecavir, this could be a convenient alternative.
This trial tests tenofovir alafenamide (a hepatitis B antiviral medicine) to see if it can prevent liver disease from getting worse in people with chronic hepatitis B who currently have stable (normal) liver blood tests and low virus levels. It may help lower the chance of developing serious liver complications over time.
This trial studies switching people with chronic hepatitis B from entecavir (ETV) to tenofovir alafenamide (TAF). It may help if you feel your current entecavir treatment isn’t working well enough or is inconvenient.
This trial tests whether a newer hepatitis B drug (tenofovir alafenamide) works as well and is as safe as the older drug (tenofovir disoproxil fumarate) for preventing hepatitis B from becoming active in people with blood cancers who are getting treatments that weaken the immune system.
This study tests tenofovir alafenamide (TAF) to lower hepatitis B in pregnant people and reduce the chance of passing it to the baby. You may be able to join if you’re pregnant with active hepatitis B and meet safety lab and pregnancy ultrasound requirements.
Hear when a new Liver Transplant trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.